Johnson & Johnson

Valuation Analysis

About the Company

Johnson & Johnson en bref

Johnson & Johnson (JNJ) is currently trading at 222,26 € with a market capitalization of 535,6 Md €. The trailing P/E ratio stands at 29.77x, with a forward P/E of 20.07x. The 52-week range spans from 144,48 € to 238,34 €; the current price is 6.7% below the yearly high. Year-over-year revenue growth stands at +6.6%. The net profit margin stands at 21.48%.

💰 Dividende

Johnson & Johnson pays an annual dividend of 4,65 € per share, representing a yield of 2.09%. The payout ratio stands at 60.79%.

📊 Avis des analystes

22 analystes évaluent Johnson & Johnson (JNJ) au consensus : Acheter. L'objectif de cours moyen est de 235,00 €, soit un potentiel de +5.73% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 164,73 € à 264,44 €.

Johnson & Johnson : la thèse d'investissement en détail

Johnson & Johnson (JNJ) operates in the Healthcare — specifically Drug Manufacturers - General — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

Le scénario haussier

With a gross margin near 68.14%, the company sits in the top tier of its industry — these are the kinds of structural margins that protect earnings during downturns. Return on equity of 25.74% places management among the most capital-efficient operators in the public market — every euro of shareholder capital is working hard. Free cash flow is positive and net margins stand at 21.48%, meaning reported earnings translate into real cash that can fund buybacks, dividends or strategic acquisitions.

Valorisation en contexte

At a PEG of 4.23, investors are paying more than three times the growth rate for each unit of earnings — that pricing assumes growth not only continues but accelerates from here.

À surveiller

• The forward P/E of 20.07x is meaningfully below the trailing 29.77x — analysts expect earnings to step up; the next earnings release is the test.

Thèse d'investissement : forces et faiblesses

Aperçu technique

Price trades above both the 50- and 200-day moving averages, with 50d above 200d — a classic bullish setup (golden-cross alignment).

Profil de risque

The data points to relatively defensive market behavior.

Trading Data

💵 Dividend Info

Related Stocks in the Same Sector

Where can I buy Johnson & Johnson?

Compare top-rated brokers — low fees, trusted providers, fully regulated.